Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 ...

Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were ...

Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET. Company Participants. Ray Furey - Executive Vice President, General Counsel & ...

Beginning Friday night, FDA employees overseeing medical devices, food ingredients and other key areas received calls and emails notifying them that their recent terminations had been “rescinded ...

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their ...